H.R. 4273 · 119th Congress (2025–2027)
Over-the-Counter Monograph Drug User Fee Amendments
This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA) through FY2030 and revises certain aspects of the program, including total fees to be collected and fee due dates.
Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the Food and Drug Administration (FDA), rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective, and include ingredients, dosages, and other requirements. OMUFA permits the FDA to collect fees from OTC drug facilities and entities requesting changes to a monograph.
The bill makes certain changes to OMUFA, including by
- revising the total facility fee revenue amount to be collected for FY2026-FY2030,
- revising due dates for facility fees,
- permitting the FDA to implement a one-time adjustment to facility fees if certain conditions exist, and
- requiring the FDA to publish facility and order request fee amounts at least 60 days before the start of each fiscal year.
Finally, the bill adds as a Tier 2 OTC monograph order request a request for the addition or modification of a testing procedure applicable to a monograph drug, provided the testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality. (Requestors seeking certain kinds of changes to a monograph are awarded a period of market exclusivity if the FDA makes the requested changes; tier 2 requests are not eligible for market exclusivity.)
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.
Reported
This bill’s path
This is H.R. 4273’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Robert E. Latta (R-OH-5)
- Cosponsors
3 cosponsors
3 original · 0 later
- Rep. Dan Crenshaw (R-TX-2)· Original · Jul 2, 2025
- Rep. Diana DeGette (D-CO-1)· Original · Jul 2, 2025
- Rep. Debbie Dingell (D-MI-6)· Original · Jul 2, 2025
- Policy area
- Health
- Subjects
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- User charges and fees
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 4 committee actions · Jul 2, 2025 – Sep 17, 2025
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Markup session held
Committee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported (Amended) by the Yeas and Nays: 51 - 0.
Sources
- Congress.gov action
- House committee actions
Reported by committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-300.
Sources
- Congress.gov action
- House floor actions
Committees
- HouseEnergy and CommerceReferred Jul 2, 2025 · Markup Jul 23, 2025 · Reported Sep 17, 2025H. Rept. 119-300
Jul 23, 2025 · Markup
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Over-the-Counter Monograph Drug User Fee Amendments
Display title, Short title · Reported in House, Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.
Official title · Introduced in House